← Eichor
Study identifier: NCT06899152 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

HepQuant: Study to Assess the Role of Blood-based Biomarkers and Quantitative MR Imaging for Patients Receiving Radiation Therapy for Liver Cancer

Condition: Liver Cancer · Hepatocellular Carcinoma · Hepatocellular Cancer  ·  Sponsor: Montefiore Medical Center

PhaseNA
Planned participants40
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This is a pilot and feasibility study assessing the role of quantitative multiparametric MRI and blood-based biomarkers for the measurement of liver function in patients receiving radiation therapy for liver cancer, including hepatocellular carcinoma (HCC), cholangiocarcinoma, or liver metastases regardless of primary histology, that are undergoing photon radiation either in the de-novo or re-irradiation setting. The goal of this study is to prospectively evaluate the feasibility of using quantitative multiparametric MRI to monitor liver function at baseline and following liver radiation therapy.

This description comes directly from the study's public registry record.

Talk to the study team

Rafi Kabarriti, MD  ·  718-405-8550  ·  rkbarri@montefiore.org

Rikin Gandhi  ·  rikin.gandhi@einsteinmed.edu

Always discuss trial participation with your own doctor first.

Locations (1)

Montefiore Medical CenterThe Bronx, New York, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06899152